Ongoing Study of Elacestrant + Targeted Therapy: ELEVATE
Panelists discuss the ELEVATE trial’s ongoing evaluation of elacestrant combined with targeted agents such as ribociclib, capivasertib, and everolimus, emphasizing the importance of optimizing dosing—such as the ribociclib reduction to 400 mg on a 3-weeks-on, 1-week-off schedule—to balance efficacy and tolerability, and highlighting the trial’s role in advancing precision combination therapies that may reshape treatment sequences in hormone receptor–positive breast cancer.
The ELEVATE trial is shaping up as a key platform study for exploring the potential of elacestrant in combination with other targeted therapies. It’s impressive how the trial is methodically finding the right dosing and safety profiles for combining elacestrant with various agents like such as ribociclib, capivasertib, and everolimus.
The recent finding that ribociclib’s dose needs to be reduced to 400 mg daily on a 3-weeks-on, 1-week-off schedule to maintain tolerability without compromising efficacy is a crucial step. It highlights the delicate balance we need to strike when combining therapies to maximize patient benefit while minimizing side adverse effects.
Overall, these early phase 1b/2 expansions suggest elacestrant combines favorably with other targeted agents, potentially opening up new combination regimens that could improve outcomes in hormone receptor-positive breast cancer. It certainly hints at a future where precision combinations, tailored to tumor biology and patient tolerability, will become the norm—continuing the exciting evolution of targeted endocrine therapy.
